Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL
Yi‐Hung Carol Tan(National Taiwan Normal University), Ravi Salgia(City Of Hope National Medical Center)
Cited by 19
Related Papers
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
|Journal for ImmunoTherapy of Cancer|2018|1.3k
c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma
|Clinical Cancer Research|2007|154
CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
|PLoS ONE|2010|105
Activated c‐Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer
|Journal of Cellular and Molecular Medicine|2002|81